Sutro Biopharma STRO Net proceeds from sales of subsidiary shares
Net proceeds from sales of subsidiary shares at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's net proceeds from sales of subsidiary shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's net proceeds from sales of subsidiary shares?
- Sutro Biopharma (STRO) reported net proceeds from sales of subsidiary shares of $103.13M in Q1 2026.
- What does net proceeds from sales of subsidiary shares mean?
- This represents the total cash proceeds received by the company from the issuance of equity securities during an initial public offering. It reflects the capital raised from public markets to fund research, development, and general corporate purposes. This metric is a key indicator of the company's ability to access external capital to support its growth strategy.